Nutraceuticals – foods that contain health-giving additives – have shown promising trial results for a range of diseases, but a lack of co-operation between the regulatory agencies of different regions is restricting their availability, which in turn is discouraging large multinationals from investing in them.

Well known nutraceutical products include Yakult and Omega-3 supplements, although many varieties exist.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In a recent survey, GBI Research found that 81% of professionals who worked in the food and pharmaceutical industry but were not involved in nutraceuticals considered unclear regulatory and legal frameworks a key restraint to the growth of the market.

And even among those who worked in the nutraceutical industry, 72% shared this opinion.

The regulatory frameworks of Europe and the US, although similar, have different product classes and definitions, and lack precise definitions of the classes of products that nutraceuticals can occupy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This leads to situations like those seen with Deplin and Souvenaid, where Deplin is unavailable in Europe, and Souvenaid is unavailable in the US – despite these products demonstrating clinical efficacy in depression and Alzheimer’s disease, respectively.

Regulatory clarity and synergy would make more products available to patients, increase revenue for manufacturers, and incentivise the development of more high-quality nutraceuticals, which would enable healthcare systems to provide more treatment options at lower costs.